Under the terms of the agreement, Albany Molecular Research (AMRI) will manufacture the active pharmaceutical ingredient in New River’s NRP104, an investigational treatment for ADHD that is currently under review with the FDA.
AMRI participated with New River in the development of the chemical process to manufacture NRP104, which is now is the subject of a collaborative development and commercialization agreement between New River and Shire.
“We are confident that AMRI is a solid choice for manufacture,” Krish Krishnan, New River’s CFO and COO, commented. “AMRI has the current capability of delivering a quality product in a timely manner, leading us to conclude that it is the best candidate for manufacturing NRP104 for an expected product launch in the first quarter of 2007.”
Financial terms of the deal were not disclosed.